An Expanded Access Program of SER-109 in patients with multiple recurrent Clostridium difficile infection (CDI)
Latest Information Update: 02 Apr 2020
At a glance
- Drugs SER 109 (Primary)
- Indications Clostridium difficile infections
- Focus Expanded access; Therapeutic Use
- 30 Mar 2020 According to a Seres Therapeutics media release, the company plans to initiate a SER-109 Expanded Access Program at selected clinical sites participating in the ongoing Phase 3 ECOSPOR III study, and the Company may also initiate the program at additional clinical sites for eligible patients to have access to SER-109.
- 16 May 2016 According to a Seres Therapeutics media release, company has initiated expanded access program at selected sites participating in the ongoing Phase 2 study
- 05 May 2016 New trial record